ClinicalTrials.Veeva

Menu
C

California Neuroscience Research Medical Group | Sherman Oaks, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gantenerumab
Aducanumab
Rimegepant
LY3002813
Donanemab
OPC-34712
BMS-708163
Rapastinel
PRX-03140
Troriluzole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 47 total trials

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people w...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: Mevidalen

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Migraine
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Pfizer logo
Bristol-Myers Squibb (BMS) logo
Roche logo
Lilly logo
Biogen logo
Biohaven logo
Otsuka logo
AbbVie logo
Allergan logo
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems